LabCompass

Mark R. Kelley

Medicine · Indiana University

OpenAlex ORCID
Established · publishing since 1998Rising activity
Hormonal Regulation and HypertensionDNA Repair MechanismsRetinal Diseases and TreatmentsEpigenetics and DNA MethylationPharmacogenetics and Drug Metabolism

Publications

66

Citations

568

Est. group size

—

Recurring co-author estimate

Active years

28

Publishing since 1998

Research summary
AI-generated

Mark R. Kelley studies a DNA-repair and redox-signaling protein called APE1/Ref-1 and how blocking its activity might treat a range of diseases. His work spans inflammatory bowel disease, retinal (eye) blood-vessel diseases, cancers such as leukemia and pancreatic tumors, and nerve damage caused by chemotherapy. The research combines basic molecular biology with efforts to develop targeted drug therapies.

APE1/Ref-1 redox signaling as a drug targetDNA repair mechanisms and oxidative damageInflammatory bowel disease treatmentRetinal neovascular (eye) diseaseCancer biology and neurotoxicity

Publication activity has generally grown over the past decade, with a notable spike in 2023 and an average of about nine publications per year over the last five years.

Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026

Funding
Public award records

Current awards run through August 2028 — about 2 years of funding on record from today. Awards are often renewed, so this is what is currently public, not a forecast.

  • ActiveNIH T32CA272370through Aug 2028 · $164k awarded

    Pediatric and Adult Translational Cancer Drug Discovery and Development Training Program (PACT-D3)

  • ActiveNIH R01CA282478through Jul 2028 · $479k awarded

    Metabolic flux analysis and PDX models to understand therapeutic vulnerabilities following inhibition of Ref-1 redox signaling in pancreatic cancer

9 earlier awards
  • NIH R01EY031939Jul 2020 – Jun 2025 · $459k awarded

    Targeting the Ref-1 signaling node for treating ocular neovascularization

  • NIH R01CA167291Dec 2012 – Feb 2025 · $484k awarded

    Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations

  • NIH P30CA082709Sep 1999 – Aug 2024 · $323k awarded

    Developmental Funds

  • NIH R01CA231267Sep 2018 – Aug 2023 · $461k awarded

    (PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)

  • NIH R01CA205166Mar 2017 – Mar 2023 · $538k awarded

    (PQ9)Mechanistic Role of APE1 and BER in chemotherapy-induced peripheral neuropathy

  • NIH R21NS091667Jan 2015 – Jan 2018 · $195k awarded

    DNA damage and repair in inflammation-induced peripheral sensitization

  • NIH R01CA121168Mar 2008 – Jan 2014 · $405k awarded

    The Role of Ape1 in Neurotoxicity of Cancer Treatments

  • NIH R01CA106298Apr 2004 – Apr 2010 · $286k awarded

    Imbalancing DNA BER to enhance Ovarian Tumor Sensitivity

  • NIH R01CA094025Aug 2003 – Jul 2009 · $209k awarded

    Therapeutic/Mechanistic Role of Ape1 in Germ Cell Tumors

Matched to public NIH RePORTER and NSF records by name and institution. Awards from other agencies are not shown, and a match is not always found — this list may be incomplete.

In context
Among 5,073 established Medicine PIs within our index
Citations: 568cohort median 2,525
h-index: 13cohort median 24
Publications / year (recent): 9.2cohort median 4.8

Typically publishes in teams of ~7 · 14% small-team papers (≤3 authors) · across 14 venues

Publication cadence
Publications per year over the last 10 years — averaging 9.2/year recently
2017: 1 publication172018: 4 publications182019: 1 publication192020: 7 publications202021: 6 publications212022: 7 publications222023: 28 publications28232024: 3 publications242025: 8 publications2526
Collaborators per year
Distinct co-authors at Indiana University each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.
2017: 0 collaborators at the same institution2018: 0 collaborators at the same institution2019: 0 collaborators at the same institution2020: 0 collaborators at the same institution2021: 1 collaborator at the same institution2022: 0 collaborators at the same institution2023: 5 collaborators at the same institution2024: 0 collaborators at the same institution2025: 0 collaborators at the same institution1719212325
Recent publications
Publishes in
  • International Journal of Molecular Sciences×3
  • Redox Biology×3
  • The FASEB Journal×3
  • Gastroenterology×3
  • Journal of Pharmacology and Experimental Therapeutics×2
Similar researchers
By research-topic overlap

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Sep 1, 2026.

Claim or correct this profile